Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Sep;26(9):1102-1105.
doi: 10.1111/acem.13822. Epub 2019 Aug 1.

Resolution of Acute Priapism in Two Children With Sickle Cell Disease Who Received Nitrous Oxide

Affiliations
Case Reports

Resolution of Acute Priapism in Two Children With Sickle Cell Disease Who Received Nitrous Oxide

Michael H Greenwald et al. Acad Emerg Med. 2019 Sep.

Abstract

Background: Nitrous oxide (N O) is an inhalational medication that has anxiolytic, amnestic, potent venodilatory and mild-to-moderate analgesic properties commonly used in the emergency department (ED) setting. N2 O has a rapid onset of action (<5 minutes) and recovery (<5 minutes) and can be quickly titrated to effect without the need for IV access. It has few side effects, does not require renal or hepatic metabolism for excretion and has no reports of allergic reaction. Priapism is a serious complication of sickle cell disease (SCD) affecting approximately 35% of males, with an adverse impact on quality of life. Treatment options are limited and not evidence based, including hydration, alkalization, analgesia, oxygenation to prevent further sickling, and exchange transfusion. Patients who do not respond within 4 hours often require a painful invasive procedure that includes aspiration of blood from the corpus cavernosum and phenylephrine injections. Case reports have described a therapeutic benefit from oral pseudoephedrine, sildenafil, and intravenous (IV) arginine, however controlled clinical trials are lacking. Although a 50:50 nitrous oxide/oxygen mix is commonly used in France to enhance analgesia in patients with SCD and vasoocclusive pain events (VOE) not sufficiently responding to IV morphine, there are no reports of its use to treat priapism. We describe the effects of N2 O for the treatment of acute priapism associated with SCD in a pediatric ED.

Methods: This is a case series of two adolescent boys with Hb-SS who on 3 separate occasions presented to the ED with acute priapism that failed oral therapy (pseudoephedrine and opioids). N2 O gas was utilized to help facilitate IV catheter placement.

Results: In each presentation (at ages 8 and 10 years for patient 1; age 15 years for patient 2), the patient experienced complete resolution of the priapism within 4-15 min of receiving N2 O (max 60%). The patients were discharged from the ED following each presentation and had no recurrence during the subsequent week.

Conclusions: Priapism is a challenging complication of SCD associated with long-term morbidity and a paucity of treatment options. Opioids are commonly used. Given the risks and inconsistent results of current recommended therapy, N2 O may represent a potential opioid-sparing treatment option for priapism presenting to the ED that warrants further investigation. Although anecdotal, N2 O inhalation is an intervention to consider during a time when a treating ED physician may have few alternatives.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure: CRM is the inventor or co-inventor of several UCSF-Benioff Children’s Hospital Oakland patents/patent-pending applications that include nutritional supplements, and biomarkers of cardiovascular disease, is an inventor of an Emory University School of Medicine patent application for a nutritional supplement, is a consultant for Pfizer, Nestle Nutritional Institute and Calithera Biosciences, Inc, and has received research support from MAST Therapeutics, the United States Food and Drug Administration, and the National Institutes of Health.

Similar articles

Cited by

References

    1. Anele UA, Le BV, Resar LM, Burnett AL. How I treat priapism. Blood 2015;125:3551–8. - PMC - PubMed
    1. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. Journal of pediatric hematology/oncology 1999;21:518–22. - PubMed
    1. Anele UA, Burnett AL. Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors. The journal of sexual medicine 2015;12:713–9. - PMC - PubMed
    1. Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. The journal of sexual medicine 2012;9:88–103. - PubMed
    1. Wang HH, Herbst KW, Rothman JA, Shah NR, Wiener JS, Routh JC. Trends in Sickle Cell Disease-related Priapism in U.S. Children’s Hospitals. Urology 2016;89:118–22. - PMC - PubMed

Publication types